Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ELUT by emailGet an email when ELUT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ELUT, unsubscribe in one click. Privacy
📣 What ELUT Says Is Next
in 2028 · “And we believe we have the team and capital to execute.” Capital Secured to Support NXT-41x Through Clearance and Commercial Launch Elutia has secured up to $26 million of additional capital to support the Company through the anticipated clearance of NXT-41x and its first full year of commercial launch in 2028, without an equity offering:”
Company press release, Aug 13, 2026 · SEC filing
fourth quarter of 2026 · “Total cash and escrow funds at March 31, 2026, were $36.5 million, comprised of $28.5 million in cash on hand and $8.0 million held in escrow related to the BioEnvelope business divestiture, with the escrowed funds expected to be released in the fourth quarter of 2026. First Quarter 2026 Financial Results Net sales and operating results discussed below reflect continuing operations.”
Company press release, May 14, 2026 · SEC filing
first half of 2027 · “The Company's interactions with the FDA during this review have helped to refine the submission package for NXT-41x, an antibiotic-eluting product, with anticipated clearance in the first half of 2027. Manufacturing Automation Supports an Expected Gross Margin Above 80%.”
Company press release, May 14, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ELUT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ELUT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.